S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Investors See Opportunity in Huge Global Demand for Lithium (Ad)
Why Invest in High-Yield Dividend Stocks?
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Closing prices for crude oil, gold and other commodities
Investors See Opportunity in Huge Global Demand for Lithium (Ad)
Look at Honeywell for a Steady and Diversified Stock
Big climate bill; Spending green bucks to boost green energy
Big climate bill: Spending green bucks to spur green energy
Investors See Opportunity in Huge Global Demand for Lithium (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Investors See Opportunity in Huge Global Demand for Lithium (Ad)
Why Invest in High-Yield Dividend Stocks?
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Closing prices for crude oil, gold and other commodities
Investors See Opportunity in Huge Global Demand for Lithium (Ad)
Look at Honeywell for a Steady and Diversified Stock
Big climate bill; Spending green bucks to boost green energy
Big climate bill: Spending green bucks to spur green energy
Investors See Opportunity in Huge Global Demand for Lithium (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Investors See Opportunity in Huge Global Demand for Lithium (Ad)
Why Invest in High-Yield Dividend Stocks?
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Closing prices for crude oil, gold and other commodities
Investors See Opportunity in Huge Global Demand for Lithium (Ad)
Look at Honeywell for a Steady and Diversified Stock
Big climate bill; Spending green bucks to boost green energy
Big climate bill: Spending green bucks to spur green energy
Investors See Opportunity in Huge Global Demand for Lithium (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Investors See Opportunity in Huge Global Demand for Lithium (Ad)
Why Invest in High-Yield Dividend Stocks?
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Closing prices for crude oil, gold and other commodities
Investors See Opportunity in Huge Global Demand for Lithium (Ad)
Look at Honeywell for a Steady and Diversified Stock
Big climate bill; Spending green bucks to boost green energy
Big climate bill: Spending green bucks to spur green energy
Investors See Opportunity in Huge Global Demand for Lithium (Ad)
NASDAQ:MACK

Merrimack Pharmaceuticals - MACK Stock Forecast, Price & News

$4.20
-0.14 (-3.23%)
(As of 08/11/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.17
$4.32
50-Day Range
$4.16
$6.24
52-Week Range
$3.66
$7.41
Volume
9,083 shs
Average Volume
59,054 shs
Market Capitalization
$56.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Merrimack Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
2.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.89mentions of Merrimack Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$188,276 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.74 out of 5 stars

Medical Sector

1012th out of 1,112 stocks

Pharmaceutical Preparations Industry

495th out of 544 stocks

MACK stock logo

About Merrimack Pharmaceuticals (NASDAQ:MACK) Stock

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Merrimack Pharmaceuticals Trading Down 3.2 %

MACK Stock opened at $4.20 on Friday. The firm has a 50 day moving average of $5.41 and a 200-day moving average of $5.72. Merrimack Pharmaceuticals has a 12-month low of $3.66 and a 12-month high of $7.41. The company has a market cap of $56.32 million, a price-to-earnings ratio of -35.00 and a beta of 1.32.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on Merrimack Pharmaceuticals in a report on Tuesday. They set a "sell" rating on the stock.

Insiders Place Their Bets

In related news, Director Noah G. Levy acquired 20,938 shares of the stock in a transaction dated Tuesday, June 14th. The stock was bought at an average cost of $5.17 per share, with a total value of $108,249.46. Following the purchase, the director now directly owns 1,010,515 shares of the company's stock, valued at $5,224,362.55. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last three months, insiders bought 35,478 shares of company stock valued at $188,276. Company insiders own 25.80% of the company's stock.

Receive MACK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MACK Stock News Headlines

Merrimack Pharmaceuticals: Out For Now
Merrimack Pharmaceuticals GAAP EPS of -$0.01
Merrimack Reports Full Year 2021 Financial Results
Merrimack Pharmaceuticals reports FY results
Thursday 1/13 Insider Buying Report: MACK, ASO
Merrimack Reports Third Quarter 2021 Financial Results
Merrimack Pharmaceuticals, Inc. (MACK)
MACK Jun 2021 15.000 call
See More Headlines
Receive MACK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MACK Company Calendar

Last Earnings
5/10/2019
Today
8/12/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MACK
CUSIP
59032810
Employees
426
Year Founded
N/A

Profitability

Net Income
$-2,450,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.02 per share

Miscellaneous

Free Float
9,950,000
Market Cap
$56.32 million
Optionable
Optionable
Beta
1.32














MACK Stock - Frequently Asked Questions

How have MACK shares performed in 2022?

Merrimack Pharmaceuticals' stock was trading at $3.91 at the beginning of the year. Since then, MACK stock has increased by 7.4% and is now trading at $4.20.
View the best growth stocks for 2022 here
.

When is Merrimack Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our MACK earnings forecast
.

How were Merrimack Pharmaceuticals' earnings last quarter?

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced its earnings results on Friday, May, 10th. The biopharmaceutical company reported ($0.78) EPS for the quarter, topping analysts' consensus estimates of ($0.92) by $0.14.

When did Merrimack Pharmaceuticals' stock split?

Merrimack Pharmaceuticals shares reverse split on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Merrimack Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Rite Aid (RAD), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Novavax (NVAX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Bausch Health Companies (BHC) and Verastem (VSTM).

What is Merrimack Pharmaceuticals' stock symbol?

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

Who are Merrimack Pharmaceuticals' major shareholders?

Merrimack Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Sepio Capital LP (2.36%), Yakira Capital Management Inc. (0.86%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Eric Andersen, Gary L Crocker, Noah G Levy and Ulrik B Nielsen.
View institutional ownership trends
.

How do I buy shares of Merrimack Pharmaceuticals?

Shares of MACK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merrimack Pharmaceuticals' stock price today?

One share of MACK stock can currently be purchased for approximately $4.20.

How much money does Merrimack Pharmaceuticals make?

Merrimack Pharmaceuticals (NASDAQ:MACK) has a market capitalization of $56.32 million. The biopharmaceutical company earns $-2,450,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis.

How many employees does Merrimack Pharmaceuticals have?

The company employs 426 workers across the globe.

How can I contact Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The official website for the company is www.merrimackpharma.com. The biopharmaceutical company can be reached via phone at 617-441-1000, via email at ir@merrimack.com, or via fax at 617-491-1386.

This page (NASDAQ:MACK) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.